GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Atorvastatin (Lipitor)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Lipitor - labeled renal guidance

Product / population
Atorvastatin (Lipitor), adult oral tablets
Renal method
Clinical renal category or population named in the cited section
Source revision
DailyMed SPL version 8, effective 2024-04-15; posted Jul 15, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Lipitor - product and source limitations

Renal impairment increases myopathy/rhabdomyolysis risk. Monitor for muscle symptoms and assess interacting drugs.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Lipitor - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Atorvastatin (Lipitor), adult oral tablets

Renal method: Clinical renal category or population named in the cited section
Source date: DailyMed SPL version 8, effective 2024-04-15; posted Jul 15, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 5.1 and 8.6

Renal impairment does not require lowering the atorvastatin dose. Renal impairment increases myopathy/rhabdomyolysis risk. Monitor for muscle symptoms and assess interacting drugs.

RDM73-lipitor-official-1 · Source locator: Renal guidance: 5.1 and 8.6

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a60cc18b-0631-4cf0-b021-9f52224ece65
Retrieved
2026-11-07
Renal-function method
Clinical renal category or population named in the cited section
Source date/version
DailyMed SPL version 8, effective 2024-04-15; posted Jul 15, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
8d3423c237e55bc028324e9f41453c6867dcb3e0c71783742286f364b61c98ef

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=atorvastatin&s1=RDM73-lipitor-official&h1=3dcbcc3b6c61683cca358090e244f1e7501992a5a05acdf5b6f0a0ad7cfb30da

Top